Bg pattern

BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Brimvera 2mg/ml eye drops, solution in single-dose container

Brimonidine tartrate

Read this package leaflet carefully before you start using this medicine, because it contains important information for you.

  • Keep this package leaflet, you may need to read it again. If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. See section 4.

Contents of the package leaflet

  1. What is Brimvera and what is it used for
  2. What you need to know before you use Brimvera
  3. How to use Brimvera
  4. Possible side effects
  5. Storage of Brimvera
  6. Contents of the pack and further information

1. What is Brimvera and what is it used for

Brimvera is used to reduce intraocular pressure.

It can be used alone, when beta-blocker eye drops are contraindicated, or with other eye drops, when the medicine alone is not sufficient to reduce an increase in intraocular pressure in the treatment of open-angle glaucoma or ocular hypertension.

The active substance of Brimvera is brimonidine tartrate, which acts by reducing the pressure inside the eye.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Brimvera

Do not use Brimvera:

  • If you are allergic to brimonidine tartrate or any of the other ingredients of this medicine (listed in section 6).
  • If you are taking monoamine oxidase inhibitors (MAOIs) or certain antidepressants. You should inform your doctor if you are taking any antidepressant medication.
  • If you are breast-feeding.
  • In children from birth to 2 years of age.

Warnings and precautions

Before starting treatment with Brimvera, inform your doctor:

  • If you suffer or have suffered from depression, decreased mental capacity, reduced blood flow to the brain, heart problems, altered blood supply to the limbs, or a blood pressure disorder.
  • If you have or have had kidney or liver problems in the past.
  • In the event that it is being administered to a child between 2 and 12 years of age, since the use of Brimvera is not recommended in this age group.

Children and adolescents

Clinical studies have not been conducted in adolescents (12 to 17 years).

The use of Brimvera is not recommended in children under 12 years of age and is contraindicated in newborns and children under 2 years of age.

Other medicines and Brimvera

Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines.

Tell your doctor if you are taking any of the following medicines:

  • for pain, sedatives, opioids, barbiturates, or if you regularly consume alcohol.
  • anesthetics.
  • medicines to treat a heart condition or to lower blood pressure.
  • medicines that can affect metabolism, such as chlorpromazine, methylphenidate, and reserpine.
  • medicines that act on the same receptor as Brimvera, such as isoprenaline and prazosin.
  • monoamine oxidase inhibitors (MAOIs) and other antidepressants.
  • medicines for any condition, including those not related to your eye condition.
  • or if the dose of any of your current medicines changes.

These may affect your treatment with Brimvera.

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Brimvera should not be used during breast-feeding.

Driving and using machines

  • Brimvera may cause blurred or abnormal vision. This effect can be exacerbated at night or with reduced lighting.
  • Brimvera can also cause drowsiness or fatigue in some patients.

If you experience any of these symptoms, do not drive or use machines until the symptoms have resolved.

3. How to use Brimvera

Follow the administration instructions indicated by your doctor exactly. Consult your doctor or pharmacist if you have any doubts.

Use in adults

The recommended dose is one drop, twice a day, in the affected eye(s), approximately 12 hours apart.

Use in children under 12 years of age

Brimvera should not be used in children under 2 years of age.

The use of Brimvera is not recommended in children between 2 and 12 years of age.

Instructions for use

  1. Wash your hands.
  2. Open the aluminum pouch and remove the block of single-dose containers.
  3. Separate a single-dose container from the strip (Fig. 1).
  4. Place the remaining single-dose containers in the pouch and close it by folding the edge. Place the pouch in the carton box.
  5. Open the single-dose container by twisting the tip. Do not touch the tip after opening the container (Fig. 2).
  6. Tilt your head back (Fig. 3).
  7. Pull down the lower eyelid with your finger and hold the single-dose container in your other hand. Squeeze the container to release one drop into the eye (Fig. 4).
  8. Close your eyes and press the inner corner of the eye with the tip of a finger for about 1 minute. This will prevent the drop from passing through the tear duct into the throat, and most of the drop will remain in the eye (Fig. 5). If necessary, repeat steps 6 to 8 with your other eye.
  9. After use, discard the single-dose container.

Series of schematic illustrations showing the application of drops in the eye from different angles

Fig. 1 Fig. 2 Fig. 3 Fig. 4 Fig. 5

If you use Brimvera with another eye drop, wait 5-15 minutes before applying the second eye drop.

If you use more Brimvera than you should

Adults

In adults who applied more drops than prescribed, the adverse effects reported were those already known for brimonidine.

Adults who accidentally ingested brimonidine eye drops experienced a decrease in blood pressure, which in some patients was followed by an increase in blood pressure.

Children

Serious adverse effects were reported in children who had accidentally ingested brimonidine eye drops. The signs included drowsiness, feeling of muscle weakness or fatigue, low body temperature, paleness, and breathing difficulties. If this happens, contact your doctor immediately.

Adults and children

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately, or call the Toxicological Information Service, phone 91 562 04 20.

If you forget to use Brimvera

If you forget to administer a dose, apply it as soon as you remember. However, if it is almost time for your next dose, you should omit the forgotten dose and then follow your regular schedule.

Do not use a double dose to make up for forgotten doses.

If you stop using Brimvera

To be effective, Brimvera must be used every day. Do not stop using Brimvera until your doctor tells you to.

If you have any doubts about the use of this product, ask your doctor or pharmacist.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been observed with brimonidine eye drops with preservatives in multidose containers and may also occur when using brimonidine eye drops without preservatives in single-dose containers:

Affecting the eye

Very common (may affect more than 1 in 10 patients):

  • Eye irritation (redness of the eye, burning, stinging, sensation of a foreign body in the eye, itching, follicles or white spots on the transparent layer covering the surface of the eye)
  • Blurred vision
  • Allergic reaction in the eye

Common (may affect up to 1 in 10 patients):

  • Local irritation (inflammation and swelling of the eyelid, swelling of the transparent layer covering the surface of the eye, sticky eyes, pain, and tearing)
  • Sensitivity to light
  • Erosion on the surface of the eye and discoloration
  • Dry eye
  • Whitening of the transparent layer covering the surface of the eye
  • Abnormal vision
  • Inflammation of the transparent layer covering the surface of the eye

Very rare (may affect up to 1 in 10,000 patients):

  • Inflammation in the eye
  • Reduced pupil size

Side effects with unknown frequency (frequency cannot be estimated from available data):

  • Itching of the eyelids
  • Inflammation of the iris, i.e., the colored part of the eye, and the ciliary body, i.e., muscles and tissue involved in focusing the eye (iridocyclitis). This condition is also called "anterior uveitis"

Affecting the body

Very common (may affect more than 1 in 10 patients):

  • Headache
  • Dry mouth
  • Fatigue/drowsiness

Common (may affect up to 1 in 10 patients):

  • Dizziness
  • Cold symptoms
  • Symptoms affecting the stomach and digestion
  • Altered taste
  • General weakness

Uncommon (may affect up to 1 in 100 patients):

  • Depression
  • Palpitations or changes in heart rate
  • Nasal dryness
  • General allergic reactions

Rare (may affect up to 1 in 1,000 patients):

  • Respiratory failure

Very rare (may affect up to 1 in 10,000 patients):

  • Insomnia
  • Fainting
  • High blood pressure
  • Low blood pressure

Side effects with unknown frequency (frequency cannot be estimated from available data):

  • Skin reactions including redness, facial inflammation, itching, rash, and dilation of blood vessels

Reporting of side effects

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this package leaflet. You can also report side effects directly through the Spanish Medicines Surveillance System for Human Use, Website: www.notificaram.es.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Brimvera

Keep this medicine out of the sight and reach of children.

Store the single-dose containers in the aluminum pouch to protect them from light.

Do not use after 3 months from opening the aluminum pouch.

Brimvera does not contain preservatives. Once opened, the contents of a single-dose container should be used immediately. You should discard the remaining solution in the container after application.

Do not use this medicine after the expiry date which is stated on the carton, pouch, and single-dose container after EXP. The expiry date is the last day of the month shown.

Medicines should not be disposed of via wastewater or household waste. Place the containers and medicines you no longer need in the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of the containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and further information

Composition of Brimvera

  • The active substance is brimonidine tartrate. 1 ml of solution contains 2.0 mg of brimonidine tartrate, equivalent to 1.3 mg of brimonidine. One drop contains 0.06-0.07 mg of brimonidine tartrate.
  • The other ingredients are poly(vinyl alcohol), sodium chloride, sodium citrate, citric acid monohydrate, water for injections, and hydrochloric acid or sodium hydroxide (for pH adjustment).

Appearance and contents of the pack

Brimvera is a clear, slightly yellow-green solution. A single-dose container contains 0.35 ml of solution. An aluminum pouch contains two strips of 5 single-dose containers each.

Brimvera is marketed in cartons containing 30, 60, or 120 single-dose containers with 0.35 ml of solution each.

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder

Esteve Pharmaceuticals, S.A.

Passeig de la Zona Franca, 109

08038 Barcelona

Manufacturer

Pharma Stulln GmbH

Werksstraße 3

92551 Stulln

Germany

This medicine is authorized in the Member States of the European Economic Area under the following names:

Austria Brimonidin sine OmniVision

France Brimonidine OmniVision

Italy Brimofree

Spain Brimvera

United Kingdom Brimonidine OmniVision

This package leaflet was approvedJuly 2023

Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

Online doctors for BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS

Discuss questions about BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
The active ingredient in BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is brimonidine. This information helps identify medicines with the same composition but different brand names.
How much does BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS cost in pharmacies?
The average pharmacy price for BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is around 15.35 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is manufactured by Esteve Pharmaceuticals S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to BRIMVERA 2 mg/ml EYE DROPS IN SOLUTION IN SINGLE-DOSE CONTAINERS?
Other medicines with the same active substance (brimonidine) include ABRADEL 2 mg/ml EYE DROPS SOLUTION, ALPHAGAN 2 mg/ml EYE DROPS SOLUTION, BRIMONIDINE VIATRIS 2 mg/ml EYE DROPS SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media